The global norovirus vaccines market is estimated to grow at a CAGR of 7.6% during the forecast period. In 2022, North America is expected to hold a market share of 61% of the global norovirus vaccines market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
The report provides clear detailed insight into the global norovirus vaccines in pipeline forecast. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Norovirus Vaccines in Pipeline forecast from 2020-2030
• Global Norovirus Vaccines in Pipeline forecast from 2020-2030 by Regional and National Market: • North America: US, Canada • EU5: Germany, France, UK, Italy, Spain • APAC: Japan, China, India, Australia, ASEAN, Rest of APAC • Central and South America: Brazil, Argentina, Rest of Central and South America • Middle East and Africa: GCC, South Africa, North Africa, Rest of MEA
• Profiles of the selected leading companies: • Calici Therapeutics • Cocrystal Pharma • PanTheryx • Takeda • Vaxart
• List and discussion of candidate vaccines
• Key Questions Answered by this Report: • What is the current size of the overall global norovirus vaccines market? How much will this market be worth from 2020 to 2030? • What are the main drivers and restraints that will shape the overall norovirus vaccine market over the next ten years? • What factors will affect that industry and market over the next ten years? • What are the largest national markets for the world vaccines? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2030? • How will market shares of the leading national markets change by 2030, and which geographical region will lead the market in 2030? • Who are the leading companies and what are their activities, results, developments and prospects? • What are some of the most prominent norovirus vaccines currently in development? • What are the main trends that will affect the world norovirus vaccines market between 2020 and 2030? • What are the main strengths, weaknesses, opportunities and threats for the market? • What are the demographic influences that will shape that industry over the next ten years? • How will the global norovirus vaccines market evolve over the forecasted period, 2020 to 2030?
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1 Report Overview 1.1 Overview of the World Norovirus Vaccines Market 1.2 Why You Should Read this Report 1.3 How This Report Delivers 1.4 Main Questions Answered by this Analytical Study 1.5 Who is This Report for? 1.6 Methods of Research and Analysis 1.7 Frequently Asked Questions (FAQ) 1.8 Associated Visiongain Reports 1.9 About Visiongain
2 Norovirus Vaccines in Pipeline Market Overview 2.1 Introduction 2.2 Market Dynamics 2.2.1 Growing Demand from Under-Developed and Developing Economies 2.2.2 Ensuring that Vaccines Benefit Global Public Health 2.2.3 Increased Investment Requirements for R&D and Manufacturing 2.2.4 Increased opportunity cost as relative investment economics converge with biologics 2.2.5 Sensitive assays have only recently been widely available 2.2.6 Routine testing is rarely performed in ongoing surveillance platforms 2.3 Global Burden of Norovirus 2.3.1 Role of Norovirus 2.3.2 Global trends of diarrheal disease in adults and children 2.4 Epidemiology of norovirus 2.4.1 Risk factors, modes and settings of transmission 2.4.2 Early childhood infections 2.4.3 Chronic health consequences associated with norovirus infection 3 Norovirus vaccines 3.1 Candidate vaccines 3.1.1 Transgenic plant-based norovirus vaccine 3.1.2 Norovirus P particle and combination vaccines 3.1.3 Trivalent norovirus /rotavirus combination vaccine 3.1.4 Takeda Pharmaceutical/Ligocyte VLP vaccine 3.2 Challenges for norovirus vaccine development 3.3 Norovirus Vaccines: Clinical Trial Landscape
4 Global Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.1 North America Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.1.1 U.S. Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.1.2 Canada Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.2 EU5 Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.2.1 Germany Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.2.2 The UK Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.2.3 France Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.2.4 Italy Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.2.5 Spain Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.3 APAC Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.3.1 Japan Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.3.2 China Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.3.3 India Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.3.4 Australia Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.3.5 ASEAN Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.3.6 Rest of APAC Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.4 Central and South America Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.4.1 Brazil Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.4.2 Argentina Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.4.3 Rest of Central and South America Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.5 MEA Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.5.1 GCC Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.5.2 South Africa Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.5.3 North Africa Norovirus Vaccine Market Forecast, 2020-2030 (USD Million) 4.5.4 Rest of MEA Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
5 Leading Companies 5.1 Takeda Pharmaceutical Company Limited 5.1.1 Company Overview 5.1.2 Financial Performance (2016-2018) 5.1.3 Pipeline Products 5.2 Vaxart 5.2.1 Company Overview 5.2.2 Financial Performance 5.2.3 Pipeline Products 5.3 Cocrystal Pharma, Inc. 5.3.1 Company Overview 5.3.2 Pipeline Products 5.4 PanTheryx 5.4.1 Company Overview 5.4.2 Pipeline Products 5.5 Calici Therapeutics 5.5.1 Company Overview 5.5.2 Pipeline Products
Appendices Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form List of Tables Table 4.1 Global Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.2 North America Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.3 U.S. Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.4 Canada Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.5 EU5 Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.6 Germany Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.7 The UK Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.8 France Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.9 Italy Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.10 Spain Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), Market Share (%), and CAGR (%), 2020-2030 Table 4.11 APAC Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), Market Share (%), and CAGR (%), 2020-2030 Table 4.12 Japan Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.13 Estimated number of hospitalized patients and deaths due to infectious gastroenteritis among adults aged ≥60 years in Japan Table 4.14 China Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), Market Share (%), and CAGR (%), 2020-2030 Table 4.15 India Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.16 Australia Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.17 ASEAN Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.18 Rest of APAC Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.19 Central and South America Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.20 Distribution of positive norovirus and rotavirus cases identified during Epidemiological Surveillance of Gastroenteritis due to Rotavirus, São Paulo, SP, 2010-2016 Table 4.21 Brazil Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.22 Argentina Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.23 Rest of Central and South America Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.24 MEA Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), Market Share (%), and CAGR (%), 2020-2030 Table 4.25 Norovirus infection in countries of the MENA region between 2000 and 2015 Table 4.26 GCC Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), Market Share (%), and CAGR (%), 2020-2030 Table 4.27 South Africa Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.28 North Africa Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 4.29 Rest of MEA Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030 Table 5.1 Takeda: Revenues 2016-2018 (JPY Million)
List of Figure Figure 4.1 Global Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.2 Global Norovirus Vaccines Market Share (%), 2022 Figure 4.3 Global Norovirus Vaccines Market Share (%), 2025 Figure 4.4 Global Norovirus Vaccines Market Share (%), 2030 Figure 4.5 North America Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.6 North America Norovirus Vaccines Market Share (%), 2022 Figure 4.7 North America Norovirus Vaccines Market Share (%), 2025 Figure 4.8 North America Norovirus Vaccines Market Share (%), 2030 Figure 4.9 U.S. Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.10 Canada Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.11 EU5 Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.12 EU5 Norovirus Vaccines Market Share (%), 2022 Figure 4.13 EU5 Norovirus Vaccines Market Share (%), 2025 Figure 4.14 EU5 Norovirus Vaccines Market Share (%), 2030 Figure 4.15 Germany Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.16 The UK Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.17 France Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.18 Italy Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.19 Spain Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.20 APAC Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.21 APAC Norovirus Vaccines Market Share (%), 2022 Figure 4.22 APAC Norovirus Vaccines Market Share (%), 2025 Figure 4.23 APAC Norovirus Vaccines Market Share (%), 2030 Figure 4.24 Japan Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.25 China Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.26 India Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.27 Australia Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.28 ASEAN Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.29 Rest of APAC Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.30 Central and South America Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.31 Central and South America Norovirus Vaccines Market Share (%), 2025 Figure 4.32 Central and South America Norovirus Vaccines Market Share (%), 2030 Figure 4.33 Brazil Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.34 Argentina Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.35 Rest of Central and South America Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.36 MEA Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.37 MEA Norovirus Vaccines Market Share (%), 2025 Figure 4.38 MEA Norovirus Vaccines Market Share (%), 2030 Figure 4.39 GCC Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.40 South Africa Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.41 North Africa Norovirus Vaccines Revenue Forecast ($m), 2020-2030 Figure 4.42 Rest of MEA Norovirus Vaccines Revenue Forecast ($m), 2020-2030
Anhui Zhifei Longcom Biopharmaceutical Co Ltd Aviragen Therapeutics, Inc. Calici Therapeutics Inc. Centers for Disease Control and Prevention (CDC) Children's Hospital Medical Center Chinese Ministry of Health Cocrystal Pharma, Inc. France Délices Inc GlaxoSmithKline Institut Pasteur of Shanghai (IPS) Janssen LigoCyte Pharmaceuticals, Inc. Merck Merck and Co., Inc. PanTheryx Pfizer Sanofi Takeda The Child Health Epidemiology Reference Group (CHERG) The Vaccine Research Center University of Zurich Vaxart WCCT Global World Health Organization (WHO) Zuellig Health Solutions Innovation Centre Zuellig Pharma
Download sample pages
Complete the form below to download your free sample pages for Global Norovirus Vaccines in Pipeline Forecast 2020-2030
The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
